GSK: phase III study shows inhaler improves asthma control.
(CercleFinance.com) - GSK said on Monday that a phase III study has showed that its Relvar Ellipta inhaler was superior to usual care treatment in improving asthma control.
The trial showed that initiation of once-daily Relvar Ellipta was superior to usual care in achieving a consistent improvement in patient's asthma control over the 12-month study duration, compared with patients who continued to take their usual medicines.
Statistically significant findings were also seen at 40 and 52 weeks.
These positive results have been simultaneously published in The Lancet journal and presented at the European Respiratory Society (ERS) international congress in Milan.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The trial showed that initiation of once-daily Relvar Ellipta was superior to usual care in achieving a consistent improvement in patient's asthma control over the 12-month study duration, compared with patients who continued to take their usual medicines.
Statistically significant findings were also seen at 40 and 52 weeks.
These positive results have been simultaneously published in The Lancet journal and presented at the European Respiratory Society (ERS) international congress in Milan.
Copyright (c) 2017 CercleFinance.com. All rights reserved.